<GlossaryTerm id="CDR0000518303"><TermName>maytansinoid DM4-conjugated humanized monoclonal antibody huC242</TermName><TermPronunciation>(may-TAN-sih-noyd DM4-KON-juh-GAY-ted HYOO-muh-nized MAH-noh-KLOH-nul AN-tee-BAH-dee...)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. It is made by linking the monoclonal antibody huC242 to a toxic substance called maytansinoid DM4. The monoclonal antibody binds to the surfaces of cancer cells and the maytansinoid DM4 enters the cells and blocks their growth. It is a type of immunotoxin. Also called huC242-DM4.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718074" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;maytansinoid DM4-conjugated humanized monoclonal antibody huC242&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718073" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anticuerpo monoclonal humanizado huC242 conjugado con maitansinoide DM4&quot;" language="es" id="_4"/><SpanishTermName>anticuerpo monoclonal humanizado huC242 conjugado con maitansinoide DM4</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. Se elabora al unir el anticuerpo monoclonal huC242 a una sustancia tóxica que se llama maitansinoide DM4. El anticuerpo monoclonal se une a las superficies de las células cancerosas y el maitansinoide DM4 entra en las células y bloquea su crecimiento. Es un tipo de inmunotoxina. También se llama huC242-DM4.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-03-16</DateFirstPublished><DateLastModified>2010-04-30</DateLastModified></GlossaryTerm>
